{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"95","value":"524"}]}],"title":"ANC at baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"244","value":"931"}]}],"title":"ANC after 2 cycles"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"ANC count at baseline and after two cycles were measured and compared. Due to the limited number of clinical responders, the changes in transfusion requirements were not measured.","dispersionType":"Standard Error","groups":[{"description":"BEX and GM-CSF were administered in 4 week cycles. BEX was given orally with food daily for 28 days at the FDA-approved dose for treatment of CTCL of 300 mg/m2 and GM-CSF was given at a daily dose of 125 µg/m2 subcutaneously for 28 days.","id":"OG000","title":"Bexarotene + GM-CSF"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Baseline and after two cycles","title":"Clinical Activity as Measured by Change in Peripheral Blood Counts and Changes in Transfusion Requirements","type":"SECONDARY","unitOfMeasure":"neutrophils/mm^3"}